Sign In
Buy INBS
$2.44
-0.100 (-3.94%)
At Close: Jun 03, 2026
Intelligent Bio Solutions Secures Key U.S. Patent, Strengthening IP Protection Ahead of Planned 2025 Market Entry
08:30am, Wednesday, 26'th Mar 2025
Company's 6 th U.S. patent adds to comprehensive IP portfolio protecting its unique drug screening technology
Intelligent Bio Solutions' FDA Clearance Process Remains on Track for 2025 U.S. Launch
09:00am, Tuesday, 25'th Mar 2025
NEW YORK, March 25, 2025 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the “Company”), a medical technology company delivering intelligent, rapid, non-invasive t
Intelligent Bio Solutions to Expand U.S. IP Portfolio with Expected Patent Grant
08:30am, Thursday, 20'th Mar 2025
NEW YORK, March 20, 2025 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the “Company”), a medical technology company delivering intelligent, rapid, non-invasive t
Intelligent Bio Solutions to Participate in the iAccess Virtual Best Ideas Spring Conference on March 25th and 26th
08:30am, Tuesday, 11'th Mar 2025
NEW YORK, March 11, 2025 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the “Company”), a medical technology company delivering intelligent, rapid, non-invasive t
NEW YORK, Feb. 21, 2025 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) (the “Company”), a medical technology company delivering intelligent, rapid, non-invasive testing solution
Intelligent Bio Solutions Inc. Announces Pricing of $2.6 Million Public Offering of Common Stock
08:30am, Thursday, 20'th Feb 2025
NEW YORK, Feb. 20, 2025 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) (the “Company”), a medical technology company delivering intelligent, rapid, non-invasive testing solution
Intelligent Bio Solutions Inc. Announces Proposed Public Offering of Common Stock
04:42pm, Wednesday, 19'th Feb 2025
NEW YORK, Feb. 19, 2025 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) (the “Company”) a medical technology company delivering intelligent, rapid, non-invasive testing solutions
Intelligent Bio Solutions Announces Fiscal Q2 2025 Financial Results and Key Operational Achievements
08:30am, Thursday, 13'th Feb 2025
Gross profit increase of 32.6% and 11-point gross profit margin increase driven by higher-margin cartridge sales Submitted FDA 510(k) and remain on track for planned expansion into multi-billion dolla
Intelligent Bio Solutions Releases Shareholder Letter Detailing 2024 Growth and 2025 U.S. Expansion Strategy
08:30am, Monday, 10'th Feb 2025
Company highlights key milestones achieved in 2024, growing revenues and progress towards U.S. expansion in 2025 Company highlights key milestones achieved in 2024, growing revenues and progress towar
Intelligent Bio Solutions Expands with UK Partnership, Driving Global Growth Ahead of Planned U.S. Launch
08:30am, Friday, 07'th Feb 2025
Avon Freight Group selects INBS' fingerprint drug testing for three UK sites, reinforcing workplace safety and efficiency
Intelligent Bio Solutions expects to achieve 32.6% Gross Profit Expansion and Increased Profitability on Higher-Margin Sales
09:00am, Thursday, 06'th Feb 2025
Gross profit expected to surge by 32.6% Unaudited revenue of $0.61 million for fiscal Q2 and $1.48 million for the six months ended December 31, 2024 Higher-margin cartridge sales driving profitabilit
Intelligent Bio Solutions Expands Global Reach with Multilingual Drug Screening System Upgrade
09:00am, Friday, 31'st Jan 2025
Multilingual upgrade will make INBS' Drug Screening System accessible to over 4 billion users worldwide, including users across the Americas, Europe, Asia and the Middle East, supporting its strategic
Intelligent Bio Solutions Adds Quantum TM to 400+ Account Portfolio Utilizing Breakthrough Fingerprint Drug Testing
09:00am, Wednesday, 29'th Jan 2025
Quantum Traffic Management transitions from saliva and urine testing to non-invasive, in-house fingerprint sweat-based drug screening
Princebuild has moved from saliva testing to INBS' fingerprint drug testing solution to implement a more streamlined, in-house solution across seven sites.
Intelligent Bio Solutions Announces 510(k) Submission to US FDA for Fingerprint Sweat-Based Drug Screening Technology
08:30am, Wednesday, 18'th Dec 2024
NEW YORK, Dec. 18, 2024 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing so
